Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor ConferencesPRNewsWire · Sep 8, 2026
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 12, 2026
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business ResultsPRNewsWire · Aug 12, 2026
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026PRNewsWire · Aug 5, 2026Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.01 | $0.05 | Beat |
| May 13, 2026 | -$0.01 | $0.22 | Beat |
| Mar 18, 2026 | $0.01 | -$0.07 | Miss |
| Nov 13, 2025 | $0.06 | $0.03 | Miss |
| Aug 14, 2025 | $0.03 | $0.00 | Miss |
| May 9, 2025 | $0.08 | -$0.05 | Miss |